Targeted agents and immunotherapies: optimizing outcomes in melanoma

Key Points Clinical therapeutics for advanced-stage melanoma have improved dramatically with the development of BRAF and MEK inhibitors, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell-death protein 1 (PD-1) blocking antibodies, and a modified oncolytic herpes virus that is...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nature reviews. Clinical oncology Ročník 14; číslo 8; s. 463 - 482
Hlavní autori:	Luke, Jason J., Flaherty, Keith T., Ribas, Antoni, Long, Georgina V.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 01.08.2017 Nature Publishing Group
Predmet:	692/699/67/1059/2325 692/699/67/1059/602 692/699/67/1813/1634 692/700/565/1436/2185 692/700/565/251 Antigen presentation Antigens Biomarkers Blocking antibodies Care and treatment Cell death Clinical trials CTLA-4 protein Cytotoxicity Decision making Drug targeting FDA approval Humans Immune checkpoint Immunotherapy Lactose Lymphocytes T MAP kinase Medicine & Public Health MEK inhibitors Melanoma Melanoma - mortality Melanoma - secondary Melanoma - therapy Metastases Metastasis Molecular Targeted Therapy Neoplasm Metastasis Oncology Oncolysis Patient outcomes Patients PD-1 protein review-article Signal transduction Skin Neoplasms - mortality Skin Neoplasms - pathology Skin Neoplasms - therapy Survival Analysis Treatment Outcome Tumors
ISSN:	1759-4774, 1759-4782, 1759-4782
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!